New Pharmaceuticals research report from GBI Research is now available from Fast Market Research

Boston, MA -- (SBWire) -- 12/10/2012 --GBI Research, the leading business intelligence provider, has released its latest research, “Gastrointestinal Disorders Therapeutics Market to 2018 - Novel Agents Targeting Irritable Bowel Syndrome (IBS), Chronic Constipation (CC) and Ulcerative Colitis (UC) to Reinvigorate the Market”, which provides insights into the gastrointestinal disorders therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. It provides in-depth analysis of the major diseases, comprising IBS, constipation, Crohn's disease, UC, Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD). The report also gives the size of the generic share in the global gastrointestinal disorders therapeutics market and in those of the US, the top five countries of Europe, and Japan, as well as treatment usage patterns and geographical distribution. Additionally, it includes insights into the R&D product pipeline and explores the competitive landscape, looking at major players and including analysis of M&A, licensing agreements and co-development deals that have taken place in the past two years.

View Full Report Details and Table of Contents

GBI Research's analysis shows that the gastrointestinal disorders therapeutics market is set to witness high generic competition in the forecast period, as major drugs used in the treatment of the aforementioned disorders are set to expire, resulting in declining revenues and allowing generics to enter the market. Nevertheless, the market will witness steady growth due to the anticipated entry of innovative new drugs in the near future. Furthermore, strong R&D in IBS, constipation, Crohn's disease and UC remains a key market driver.

Scope

- Data and analysis for the gastrointestinal disorders therapeutics markets in the leading geographies: the US; the top five countries of Europe, comprising the UK, Germany, France, Italy and Spain; Japan; and an overview of India, China and Australia
- Annualized market data for the gastrointestinal disorders therapeutics market from 2004 to 2010 and forecast to 2018
- Market data for the geographical and therapeutic landscapes, including size, share, annual cost of therapy, sales volume and treatment usage patterns for the diseased population, diagnosis population and prescription population
- Generic share in the global market and for each indication
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global market, looking at key companies such as AstraZeneca, Takeda, Johnson & Johnson , Eisai, Abbott, Shire and Salix
- Key M&A activity and licensing agreements that took place between 2010 and 2012

Reasons to Get this Report

- Align product portfolios to the markets with high growth potential

Companies Mentioned in this Report: AstraZeneca, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai Co., Ltd., Abbott Laboratories, Shire, Salix Pharmaceuticals

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth
- Irritable Bowel Syndrome (IBS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Irritable Bowel Syndrome - Pipeline Review, H1 2012
- Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2012
- Dermatology Therapeutics Market to 2018 - Novel Biologics Targeting Interleukin-17 Receptor Presents New Options in Psoriasis Treatment
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Irritable Bowel Syndrome - Pipeline Review, H2 2011
- Alizyme plc (AZM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments